ILLUMINA, INC. ILMN

Illumina's strongest current fact is not promotional language but the latest filed quarter. In its SEC EDGAR 10-Q for the period ending 2026-03-29, the company reported $1.09B of revenue from contracts with customers, $209.0M of operating income, $134.0M of net income attributable to parent and diluted earnings per share of $0.87. That gives this daily file a real earnings base rather than a thin ticker profile.

Illumina is an equity tied to a real operating business in sequencing and related life-science tools. The official issuer site supplies a product rail for Illumina Protein Prep proteomics through a trusted service provider, while the 10-Q links part of the story to SOMAmer-based next-generation sequencing library preparation kits and a 2% royalty payable to Standard BioTools on net revenues from those kit sales through January 2036. The useful point is narrow but important: the evidence connects the market symbol to products, services and contracted economics, not just to broad science language.

The filed financial rail is specific. For the 10-Q period ending 2026-03-29, Illumina reported assets of $6.56B, stockholders' equity attributable to parent of $2.68B, short-term investments of $66.0M, net cash provided by operating activities of $289.0M, payments to acquire property, plant and equipment of $38.0M, research and development expense of $240.0M, inventory, net, of $611.0M, and diluted weighted average shares outstanding of 154.0M. Those figures frame a profitable, research-heavy business with material inventory and operating cash flow in the supplied quarter.

The evidence pack does not include a chart route or current price level, so the market mechanism cannot be dressed up with invented candles, support lines or moving averages. The source route today is filings, official issuer material and SEC EDGAR. That means the report can discuss earnings, inventory, cash generation, R&D expense, product evidence, regional revenue pressure and filing activity, but it cannot claim anything about intraday trading behaviour or technical levels.

What changed in the supplied public record is a run of June insider and resale-related SEC filings, including Form 4 entries dated 2026-06-01, 2026-06-04 and 2026-06-09, plus Form 144 entries dated 2026-06-02 and 2026-06-05. The pack also includes an 8-K dated 2026-04-30 tied to first-quarter financial results for the period ended 2026-03-29, a 10-Q filed on 2026-05-04, and an 8-K dated 2026-05-26. Those filings make the current trail active, even though the supplied facts do not parse every transaction detail.

The main pressure point in the evidence is geographic. Illumina's 10-Q says total revenue in Q1 2026 was affected across all products and services by a $20M decrease in the Greater China region, primarily due to inclusion on the unreliable entities list. That fact belongs near the centre of the report because it turns a broad market concern into a filed company-specific operating issue. The deeper file would need later company commentary, parsed transaction details from the June Forms 4 and 144, and any updated official product or regional sales disclosure.